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Abstract 
Extraintestinal manifestations are common in inflammatory bowel disease; however, muscular 
involvement in Crohn disease is rarely reported. We present a case of a 26-year-old male 
with ileocolonic Crohn disease who developed sudden tenderness in both calves. Doppler 
ultrasound was negative for deep vein thrombosis. Magnetic resonance imaging of the gas-
trocnemius muscle showed high intensity signal in the muscle fibers, and muscle biopsy 
demonstrated nonspecific lymphocytic myositis. Other relevant laboratory results included 
normal antineutrophil cytoplasmic antibodies and creatine kinase as well as elevated C-
reactive protein, erythrocyte sedimentation rate, and anti-Saccharomyces cerevisiae IgG titer. 
The patient was in clinical remission, being treated with azathioprine 2.5 mg/kg. Prednisone 
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60 mg/day was initiated with rapid resolution of calf tenderness; however, tenderness soon 
returned when the dose was tapered to 10 mg/day. Subsequently, prednisone and azathio-
prine were discontinued, and adalimumab was started at standard induction and mainte-
nance doses. The patient’s symptoms resolved shortly after the first induction dose. A repeat 
magnetic resonance imaging of the calves – 3 months after starting adalimumab – showed 
complete resolution of muscle inflammation. To our knowledge, this is the first case of gas-
trocnemius myositis – a rare extraintestinal manifestation of Crohn disease – successfully 
treated with anti-tumor necrosis factor agents. © 2016 The Author(s) 
 Published by S. Karger AG, Basel 
Introduction 
Inflammatory bowel diseases (IBD), which include Crohn disease (CD) and ulcerative 
colitis, may be associated with a variety of extraintestinal manifestations (EIMs) that can 
cause greater morbidity than the underlying intestinal disease and may represent the first 
sign of IBD. Since EIMs can involve multiple organ systems, some authors believe that IBD is 
a systemic disorder with predominant bowel manifestations. As many as 36% of the IBD 
patients have at least one EIM: some correlate to the activity of bowel inflammation (joint, 
skin, and ocular manifestations), some to small bowel dysfunction (cholelithiasis or nephro-
lithiasis), while others are nonspecific disorders (osteoporosis or hepatobiliary disease) [1]. 
The most frequent EIMs in IBD are arthropathies (4–23%), followed by cutaneous manifes-
tations (2–34%), ocular manifestations (4–12%), hepatobiliary diseases (5–15%), and met-
abolic bone diseases [2]. Muscular involvement in IBD is rarely reported in the literature [3]. 
Case Presentation 
A 26-year-old male with a 6-year history of ileocolonic CD presented with mild diarrhea 
and sudden tenderness in both calves and no other symptoms. His CD at diagnosis involved 
the terminal ileum and cecum and was initially treated with a cycle of prednisone 60 mg 
daily for 4 weeks and azathioprine 2.5 mg/kg daily. Azathioprine was then continued in 
monotherapy, and the patient remained in clinical remission with normal inflammatory 
markers (fecal calprotectin and C-reactive protein) for the following 5 years. His past medi-
cal history included only allergic rhinitis. 
On physical examination, calves bilaterally were tender on palpation; no rash, skin le-
sion, or signs of systemic vasculitis were observed. Hematologic investigations showed ele-
vated C-reactive protein at 14.30 mg/L (normal 0–5), erythrocyte sedimentation rate at 31 
mm/h (normal 1–10), and positive anti-Saccharomyces cerevisiae Ig G [ASCA IgG] titer at 
1:160. Other laboratory tests including antineutrophil cytoplasmic antibodies [c-ANCA], 
creatine kinase [CK], antinuclear antibodies, anti-smooth-muscle antibodies, antimitochon-
drial antibodies, and anti-Jo-1 antibodies were within normal limits. 
Ultrasound Doppler studies of the lower extremities excluded deep vein thrombosis. 
Magnetic resonance imaging [MRI] of the legs showed bilateral high-intensity signal in the 
gastrocnemius muscle fibers beneath the muscle membrane spreading to the right flexor 
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muscle of the hallux and the tibialis anterior – a picture consistent with myositis (Fig. 1). 
Electromyography showed neither nerve nor muscle abnormalities. Subsequently, a gas-
trocnemius muscle biopsy was performed, which showed nonspecific lymphocytic myositis 
(Fig. 2). A colonoscopy was also performed to assess intestinal disease activity, which 
showed few aphthous ulcers in the ileum (simple endoscopic CD score of 3). 
The patient was started on prednisone 60 mg daily, resulting in complete clinical remis-
sion of his myositis within a few days. After 1 month, prednisone was tapered at 10 mg every 
other week. However, at the dose of 10 mg daily, the patient experienced recurrence of 
symptoms with calve pain. Prednisone was increased to 60 mg daily, and after 1 month it 
was slowly tapered by 5 mg every other week. Azathioprine was maintained all along at the 
dose of 2.5 mg/kg daily. Once again, tapering prednisone below 10 mg daily resulted in 
symptom relapse. At this point, prednisone and azathioprine were discontinued and ada-
limumab was initiated at regular induction (160/80 mg) and maintenance (40 mg every 
other week) doses. The patient became completely asymptomatic few days after the first 
induction dose. Repeat MRI 3 months later did not show any significant inflammation of the 
gastrocnemius muscles (Fig. 3). After 9 months of adalimumab therapy with the subject still 
asymptomatic, azathioprine was reintroduced at a dose of 2.5 mg/kg daily, and after 3 addi-
tional months, only azathioprine was continued. 1 year after adalimumab discontinuation, 
the patient remained in full clinical remission from myositis while on azathioprine mono-
therapy. 
Discussion 
We report here the case of a CD patient who developed gastrocnemius myositis – appar-
ently as an EIM – with normal CK and an elevated ASCA IgG titer. Published case reports of 
gastrocnemius myalgia linked to CD have shown similar prevalence in both genders, with 
patient age ranging from 19 to 50 years. Muscle histology showed granulomatous myositis in 
2 cases [4, 5], nonspecific myositis in 4 cases [6–8, 11], and vasculitis in 3 other cases [9, 10]. 
Most cases, as well as our own, had normal serum levels of CK and c-ANCA. Only 1 case 
presented with high c-ANCA titers [11]. The main features of reported cases of gastrocnemi-
us myalgia associated with CD are summarized in Table 1. All cases of calf-limited myalgia 
reported in the literature responded to prednisolone [4, 6–12] except 1 [5]. In 2 young fe-
males, a combination treatment of prednisolone plus azathioprine or cyclophosphamide [10] 
seemed to be effective. 
Our patient initially responded to prednisone, but his symptoms quickly relapsed after 
the dose was lowered below 10 mg/day. This case appears to differ from the others since 
this is the first case in which ASCA positivity (frequently reported in CD) was detected. It is 
also the first case of gastrocnemius myositis successfully treated with an anti-tumor necrosis 
factor (TNF) agent. 
Anecdotal reports suggest that TNF inhibitors can be helpful in the treatment of derma-
tomyositis and polymyositis, although other reports do not show a benefit or even show that 
these disorders could actually be the result of such treatment (e.g., the onset of myositis has 
been reported in rheumatoid arthritis patients during anti-TNF therapy) [13–15]. The myo-
sitis in IBD patients differs from the myositis resulting from other causes since it does not 
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appear to be associated with an increased CK or with specific autoantibodies. It also does not 
show typical electromyography or histology features. Its relationship to IBD may explain 
why this type of myositis, but not others, might respond to anti-TNF therapy. 
In conclusion, gastrocnemius myositis can be a rare EIM of CD, which may be particular-
ly troublesome for the patient and refractory to conventional therapies. Our case report is 
the first in the literature that describes a case successfully managed with anti-TNF agents. 
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Fig. 1. Axial MRI of the calves. T2-weighted spin-echo MR images show diffuse myositis pattern involving 
several different muscle groups, most marked in the medial and lateral head of the gastrocnemius muscles 
(arrows). 
 
 
 
Fig. 2. Histological findings of calf muscle biopsy (HE. ×20). Lymphocytic infiltration in striated muscle cells 
with typical aspects of cellular regression. 
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Fig. 3. Axial MRI of the calves during treatment with adalimumab. T2-weighted spin-echo MR images 
demonstrate the absence of inflammation in the previously involved muscle groups (for comparison, see 
Fig. 1). 
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Table 1. Features of reported cases of gastrocnemius myalgia in CD 
      
      
First author [ref.] Age, 
years 
Sex Laboratory  
findings 
Muscle 
histology 
Treatment 
      
      
Ménard [4] 44 M normal CK granulomatous 
myositis 
prednisolone 
Gilliam [9] 19 M normal CK vasculitis prednisolone 
Hall [11] 32 F normal CK myositis prednisolone 
Drabble [12] 50 M normal CK not performed prednisolone 
Diószeghy [5] 41 M normal CK 
 
granulomatous 
myositis 
no response to steroids or 
nonsteroidal 
anti-inflammatory drugs 
Disdier [10] 21 F normal CK vasculitis prednisolone 
26 F normal CK 
 
vasculitis prednisolone and 
cyclophosphamide 
Christopoulos [6] 19 F normal CK 
c-ANCA + 
myositis prednisolone 
Shimoyama [7] 33 F elevated CK 
CD68 + 
myositis mesalamine, colon 
surgery 
Mogul [8] 15 M normal CK 
normal ASCA 
normal ANCA 
myositis methylprednisolone,  
methotrexate 
Current report 26 M normal CK 
elevated ASCA IgG 
normal c-ANCA 
myositis adalimumab, then 
azathioprine 
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